Nirsevimab is the first investigational long-acting antibody designed to protect all infants for the respiratory syncytial virus season with a single dose
The funds will be used to expand digital product offerings, grow their online customer base, and launch their flagship clinic in Bengaluru
New subsidiaries to be established in Malaysia, Taiwan, Singapore, and Hong Kong
The device will facilitate the treatment of cerebral vasospasm following hemorrhagic stroke
The capex during the last nine months has been around Rs 110 crores which is all funded through internal accruals
TRIS AMINO HCl is widely used as a diagnostic reagent and as a downstream processing buffer in the purification of commercial biopharmaceuticals
BDR Pharmaceuticals is a home-grown company with operations in India and overseas. It’s known for its formulations portfolio and has a presence in specialty medicines. The company has ambitious plans as it has ramped up capacity and looking to foray into regulated markets. Raheel Shah, Director, BDR Group of Companies shares his insights in an interview with Thomas C Thottathil, Editor, Indian Pharma Post
It will open new frontier for south-to-south collaboration and innovation transfer
The service has already been initiated in Maharashtra but being net-based it is easily available for patients all across the country
She holds a Masters degree in Genetics along with a Ph.D. in Biochemistry
Subscribe To Our Newsletter & Stay Updated
